At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ERNA Eterna Therapeutics Inc.
Market Closed 06-18 16:00:00 EDT
6.20
+0.31
+5.26%
盘后6.08
-0.12-1.94%
19:51 EDT
High6.20Low5.62Vol34.71K
Open6.04D1 Closing5.89Amplitude9.85%
Mkt Cap7.23MTradable Cap5.07MTotal Shares1.17M
T/O207.16KT/O Rate4.24%Tradable Shares817.98K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ernexa expects FDA review of ERNA-101 IND in Q4 2026
Reuters  ·  06-17 21:27
Ernexa expects FDA review of ERNA-101 IND in Q4 2026
Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026
THOMSON REUTERS  ·  06-17 20:48
Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
GlobeNewswire  ·  06-17 20:47
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
GlobeNewswire  ·  06-09
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3
TIPRANKS  ·  05-27
Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
GlobeNewswire  ·  05-27
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
GlobeNewswire  ·  05-20
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:42 PM
Reuters  ·  05-16
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:42 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM
Reuters  ·  05-12
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM
Ernexa Therapeutics announces annual shareholder meeting
Reuters  ·  05-12
Ernexa Therapeutics announces annual shareholder meeting
Ernexa Q1 net loss narrows 32.87% to $5.51 million; no revenue
Reuters  ·  05-12
Ernexa Q1 net loss narrows 32.87% to $5.51 million; no revenue
Ernexa Therapeutics to join Virtual Investor Closing Bell event
Reuters  ·  05-11
Ernexa Therapeutics to join Virtual Investor Closing Bell event
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
GlobeNewswire  ·  05-11
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
Ernexa Therapeutics initiated with a Buy at Brookline
TIPRANKS  ·  05-08
Ernexa Therapeutics initiated with a Buy at Brookline
Ernexa Therapeutics announces new ERNA-101 preclinical data
TIPRANKS  ·  05-07
Ernexa Therapeutics announces new ERNA-101 preclinical data
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
Reuters  ·  05-06
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models
Reuters  ·  05-06
Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
Reuters  ·  05-03
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
GlobeNewswire  ·  04-30
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
Ernexa Therapeutics authorizes 1-for-10 to 1-for-25 reverse stock split to meet Nasdaq bid rule
Reuters  ·  04-13
Ernexa Therapeutics authorizes 1-for-10 to 1-for-25 reverse stock split to meet Nasdaq bid rule

Introduction

Company Name.
Eterna Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Issue price:
--